FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Verity Saunders

Research Profile

Chemicals & Drugs

Disorders

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Concepts & Ideas

Procedures

Drug Screening Assays, Antitumor

Physiology

Drug Resistance, Neoplasm

Phenomena

Phosphorylation

Genes & Molecular Sequences

Genes, abl

Anatomy

Chromosomes, Human, Pair 9

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
J Wang; R J D'Andrea; A Frede; K Groot-Obbink; T P Hughes; C H Kok; M Osborn; Verity A Saunders; A A Somogyi; Deborah L White
Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.
Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Amity Venables; Stephanie Zrim; Andrew C W Zannettino; Kevin Lynch; Paul W Manley; Timothy Hughes
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
Deborah White; Verity A Saunders; Andrew Grigg; Chris Arthur; Robin Filshie; Michael F Leahy; Kevin Lynch; L Bik To; Timothy Hughes
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Verity Saunders (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2012: J Wang; R J D'Andrea; A Frede; K Groot-Obbink; T P Hughes; C H Kok; M Osborn; Verity A Saunders; A A Somogyi; Deborah L White
Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.
British journal of cancer 2012;106(11):1772-8.
2007: Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Amity Venables; Stephanie Zrim; Andrew C W Zannettino; Kevin Lynch; Paul W Manley; Timothy Hughes
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
Blood 2007;110(12):4064-72.
2007: Deborah White; Verity A Saunders; Andrew Grigg; Chris Arthur; Robin Filshie; Michael F Leahy; Kevin Lynch; L Bik To; Timothy Hughes
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4445-51.
2007: Deborah L White; Verity A Saunders; Steven R Quinn; Paul W Manley; Timothy P Hughes
Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.
Blood 2007;109(8):3609-10.
2006: Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Andrew C W Zannettino; Antony C Cambareri; Steven R Quinn; Paul W Manley; Timothy P Hughes
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
Blood 2006;108(2):697-704.
2005: Deborah White; Verity A Saunders; A Bruce Lyons; Susan Branford; Andrew Grigg; L Bik To; Timothy Hughes
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.
Blood 2005;106(7):2520-6.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.